Please login to the form below

Not currently logged in
Email:
Password:

Linzess

This page shows the latest Linzess news and features for those working in and with pharma, biotech and healthcare.

NICE backs Allergan's IBS therapy Truberzi

NICE backs Allergan's IBS therapy Truberzi

includes Linzess (linaclotide) for IBS with constipation. ... Viberzi sales in the US were almost $73m in the first six months of the year, almost a three-fold increase over the same period a year earlier, while Linzess contributed

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... All eyes will now be on the performance

  • Pharma deals during April 2014 Pharma deals during April 2014

    Forest is building a leading position in the $38bn gastroenterology (GI) market adding eluxadoline to its broader GI portfolio including Linzess. Actavis has consented to Forest's acquisition of Furiex. The

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Ironwood appoints Edward Owens to board Ironwood appoints Edward Owens to board

    Owens is a former partner at investments advisor Wellington Management, and joins the US-based biopharma at a time of growth following the approval of Linzess (linaclotide) in the US for ... The execution of a successful launch of Linzess should provide

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics